Keyphrases
Multiple Sclerosis
100%
National Cohort Study
86%
Teriflunomide
82%
Disease-modifying Therapy
48%
Relapsing-remitting multiple Sclerosis
39%
Expanded Disability Status Scale
39%
Confidence Interval
30%
Disease Activity
29%
Comparative Effectiveness
29%
Real-world Outcomes
27%
Treatment Escalation
27%
Multiple Sclerosis Treatment
27%
Effective Therapy
27%
Delayed Neuropsychiatric Syndrome
27%
High Efficacy Disease-modifying Therapies
27%
Highly Effective
27%
Ocrelizumab
27%
Rituximab
27%
Prognostic Factors
27%
Newly Diagnosed
27%
COVID-19 Vaccine
27%
Acute Disseminated Encephalomyelitis
27%
Older Women
27%
Carbon Monoxide Poisoning
27%
Ad26
27%
Dimethyl Fumarate
27%
Disease Risk
22%
Annualized Relapse Rate
21%
First Relapse
18%
Disability Worsening
13%
Rate Ratio
11%
Hazard Ratio
11%
Relapse Rate
9%
Lesion Load
9%
Propensity Score Matching
9%
First Treatment
9%
MSBase
8%
Nave
8%
COVID-19
7%
Severe Acute Respiratory Syndrome coronavirus-2 Vaccine
7%
Treatment Outcome
7%
T2 Lesions
7%
Diffusion Magnetic Resonance Imaging (dMRI)
7%
Propensity Score
6%
Non-inferiority
6%
Disability Accumulation
6%
MS Registry
6%
High Risk
6%
Memory Impairment
5%
Diffuse White
5%
Medicine and Dentistry
Disease Modifying Therapy
54%
Cohort Analysis
54%
Multiple Sclerosis
48%
Recurrence Risk
37%
Disease
27%
COVID-19 Vaccine
27%
Fumaric Acid Dimethyl Ester
27%
Carbon Monoxide Intoxication
27%
Acute Disseminated Encephalomyelitis
27%
Teriflunomide
27%
Expanded Disability Status Scale
19%
Severe Acute Respiratory Syndrome Coronavirus 2
15%
Combination Therapy
11%
Symptom
7%
Cerebral Hemisphere
7%
Hazard Ratio
6%
Propensity Score Matching
6%
Magnetic Resonance Imaging
6%
Smoke
5%
Diffusion MRI
5%
Unsteady Gait
5%
Sequela
5%
Oxygen Therapy
5%
Hyperbaric Medicine
5%
Hemisphere
5%
Memory Disorder
5%
White Matter Lesion
5%
Magnetic Resonance Imaging of Brain
5%
Carbon Monoxide
5%
